Risperdal settlement to cost J&J $181 million

Share this content:
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes. The payouts will go to 36 states, plus the District of Columbia, which brought consumer fraud charges against Janssen for allegedly deceptively marketing the drug Risperdal to providers treating patients with Alzheimer's and dementia, Reuters reported. The drug, which is intended to treat schizophrenia, is not approved for these conditions.

 

close

Next Article in Products